Saturnus Bio raised $50 million to advance the development of its portfolio of first-in-class, non-viral gene-modulating therapies for the treatment of rare monogenic cardiomyopathies that drive heart failure.
Saturnus Bio raised $50 million to advance the development of its portfolio of first-in-class, non-viral gene-modulating therapies for the treatment of rare monogenic cardiomyopathies that drive heart failure.